Cover Image
Market Research Report

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2019

Published by Global Markets Direct Product code 229775
Published Content info 217 Pages
Delivery time: 1-2 business days
Price
Back to Top
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2019
Published: December 16, 2019 Content info: 217 Pages
Description

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis - Pipeline Review, H2 2019, provides an overview of the Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline landscape.

Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine's bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ankylosing Spondylitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 10, 2, 8, 1, 16 and 7 respectively.

Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Ankylosing Spondylitis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ankylosing Spondylitis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ankylosing Spondylitis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ankylosing Spondylitis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11688IDB

Table of Contents

  • Introduction
  • Spinal Cord Injury - Overview
  • Spinal Cord Injury - Therapeutics Development
  • Spinal Cord Injury - Therapeutics Assessment
  • Spinal Cord Injury - Companies Involved in Therapeutics Development
  • Spinal Cord Injury - Drug Profiles
  • Spinal Cord Injury - Dormant Projects
  • Spinal Cord Injury - Discontinued Products
  • Spinal Cord Injury - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by AbbVie Inc, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Alvotech ehf, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Amgen Inc, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Beijing Eastern Biotech Co Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Bio-Thera Solutions Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocad, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocon Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by BioXpress Therapeutics SA, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Clover Biopharmaceuticals, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by DNX Biopharmaceuticals Inc, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by FunPep Co Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Galapagos NV, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Hengenix Biotech Inc, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Huabo Biopharm Co Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Hualan Biological Engineering Inc, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Immunwork Inc, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Innovent Biologics Inc, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by InSight Biopharmaceuticals Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Izana Bioscience Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by JiangSu Qyuns Therapeutics Co Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Lupin Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Mycenax Biotech Inc, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by NeuClone Pty Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Nimbus Therapeutics LLC, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Novartis AG, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Pfizer Inc, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Pharmapraxis, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by RNAx Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shandong Boan Biological Technology Co Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shandong Danhong Pharmaceutical Co Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shanghai Junshi Bioscience Co Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Siam Bioscience Co Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sino Biopharmaceutical Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by UCB SA, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Wuhan Institute of Biological Products Co Ltd, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Xbrane Biopharma AB, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top